Calquence Granted Priority Review in the U.S. for Patients With Untreated Mantle Cell Lymphoma
October 04, 2024
October 04, 2024
WILMINGTON, Delaware, Oct. 4 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Based on ECHO Phase III trial which demonstrated CALQUENCE combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Submission to be reviewed under Project Orbis
* * *
AstraZeneca's supplemental New Drug Application (sNDA) for CALQUENCE (acalabrutinib) has . . .
* * *
Based on ECHO Phase III trial which demonstrated CALQUENCE combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Submission to be reviewed under Project Orbis
* * *
AstraZeneca's supplemental New Drug Application (sNDA) for CALQUENCE (acalabrutinib) has . . .